The benefit of population-based studies for older patients with acute myeloid leukemia

about

The benefit of population-based studies for older patients with acute myeloid leukemia

Item

http://www.wikidata.org/entity/Q36662009

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The benefit of population-based studies for older patients with acute myeloid leukemia

@ast

The benefit of population-based studies for older patients with acute myeloid leukemia

@en

type

Item

label

The benefit of population-based studies for older patients with acute myeloid leukemia

@ast

The benefit of population-based studies for older patients with acute myeloid leukemia

@en

prefLabel

The benefit of population-based studies for older patients with acute myeloid leukemia

@ast

The benefit of population-based studies for older patients with acute myeloid leukemia

@en

P1476

The benefit of population-based studies for older patients with acute myeloid leukemia

@en

P2860

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Age and acute myeloid leukemia.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Acute myeloid leukemia in the real world: why population-based registries are needed.

Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.

Survival for older patients with acute myeloid leukemia: a population-based study

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

"I am older, not elderly," said the patient with acute myeloid leukemia.

Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.

P304

1781-1782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2012.080242

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Torsten Haferlach

Ulrike Bacher

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23204478

http://www.w3.org/2001/XMLSchema#string

P932

3590082

http://www.w3.org/2001/XMLSchema#string